Morphine versus oxycodone in pancreatic cancer pain: A randomized controlled study

Clinical Journal of Pain

Volumn 26, Issue 9, 2010, Pages 794-797

  Mercadante, Sebastiano ^a   Tirelli, Walter ^b   David, Fabrizio ^a   Arcara, Carlo ^b   Fulfaro, Fabio ^b   Casuccio, Alessandra ^c   Gebbia, Vittorio ^b  

^a LA MADDALENA CANCER CENTER   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c Hospice Sacro Cuore   (Italy)

Author keywords

morphine; opioids; oxycodone; pancreatic cancer pain; visceral pain

Indexed keywords

BUPRENORPHINE; FENTANYL; MORPHINE; OXYCODONE;

ADULT; ANALGESIA; ARTICLE; CANCER PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SUBSTITUTION; FEMALE; HOSPITAL ADMISSION; HUMAN; INTESTINE OBSTRUCTION; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE FORMULATION; TREATMENT OUTCOME;

EID: 77958490955     PISSN: 07498047     EISSN: 15365409     Source Type: Journal    
DOI: 10.1097/AJP.0b013e3181ecd895     Document Type: Article

References (24)

1. Hanks GW; Expert Working group of the Research Network of the European Association for Palliative Care. Morphine and alternative opioids in cancer pain: the EAPC recommenda-tions. Br J Cancer. 2001;84:587-593.
2. Reid CM, Martin RM, Sterne JA, et al. Oxycodone for cancer-related pain: meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166:837-843.
3. Nielsen C, Ross F, Lotfipour S, et al. Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain. 2007;132:289-300.
4. Riviere P. Peripheral kappa-opioid agonists for visceral pain. Br J Pharmacol. 2004;141:1331-1334.
5. Ross FB, Smith MT. The intrinsic antinociceptive effects of oxycodone appear to be κ-opioid receptor mediated. Pain. 1997;73:151-157.
6. Staahl C, Dimcevski G, Andersen S, et al. Differential effect of opioids in patients with chronic pancreatitis: an experimental study. Scand J Gastroenterol. 2007;42:383-390.
7. Nielsen CK, Ross FB, Smith MT. Incomplete, asymmetric and route-dependent cross-tolerance between oxycodone and mor-phine in the dark agouti rat. J Pharmacol Exp Ther. 2000;295: 91-99.
8. Staahl C, Christrup L, Andersen S, et al. A comparative study of oxycodone and morphine in a multimodal, tissue-differentiated experimental model. Pain. 2006;123:28-36.
9. Staahl C, Upton R, Foster DJ, et al. Pharmacokinetic-pharmacodynamic modelling of morphine and oxycodone concentrations and analgesic effect in a multimodal experi-mental pain model. J Clin Pharmacol. 2008;48:619-631.
10. Beardsley PM, Aceto MD, Cook CD, et al. Discriminative stimulus, reinforcing, physical dependence, and antinociceptive effects of oxycodone in mice, rats, and rhesus monkeys. Exp Clin Psychopharmacol. 2004;12:163-172.
11. Arendt-Nielsen L, Olesen AE, Staahl C, et al. Analgesic efficacy of peripheral kappa-opioid receptor agonist CR665 compared to oxycodone in a multi-modal, multi-tissue experi-mental human pain model: selective effect on visceral pain. Anesthesiology. 2009;111:616-624.
12. Mercadante S, Catala E, Arcuri E, et al. Celiac plexus block for pancreatic cancer pain: factors influencing pain, symptoms and quality of life. J Pain Symptom Manage. 2003;26: 1140-1147.
13. Bruera E, Belzile M, Pituskin E, et al. Randomized, double blind, crossover trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol. 1998;16:3222-3229.
14. Heiskanen T, Kalso E. Controlled release oxycodone and morphine in cancer related pain. Pain. 1997;73:37-45.
15. Mercadante S, Fulfaro F, Casuccio A, et al. Investigation of an opioid response categorization in advanced cancer patients. J Pain Symptom Manage. 1999;18:347-352. (Pubitemid 29528470)
16. Smith MT. Differences between and combination of opioids re-visited. Curr Opin Anaesthesiol. 2008;21:596-601.
17. Eisenach JC, Carpenter R, Curry R. Analgesia from a peripherally active kappa-opioid receptor agonist in patients with chronic pancreatitis. Pain. 2003;101:89-95.
18. Vanderah TW, Schteingart CD, Trojnar J, et al. FE200041 (D-Phe-D-Phe-D-Nle-D-Arg-NH2): a peripheral efficacious κ-opioid agonist with unprecedented selectivity. J Pharmacol Exp Ther. 2004;310:326-333.
19. Peckam EM, Traynor JR. Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats. J Pharmacol Exp Ther. 2006; 316:1195-1201.
20. Kalso E. How different is oxycodone from morphine? Pain. 2007;132:227-228.
21. Mercadante S, Porzio G, Ferrera P, et al. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain. 2008;12:1040-1046.
22. Lindsay T, Jonas B, Sevcik M, et al. Pancreatic cancer pain and its correlation with changes in tumor vasculature, macrophage infiltration, neuronal innervation, body weight and disease progression. Pain. 2005;119:233-246.
23. Lemberg K, Kontinen V, Siskonen A, et al. Antinociception by spinal and systemic oxycodone: why does the route make a difference? Anesthesiology. 2006;105:801-812.
24. Mazzoccato C, Sweeney C, Bruera E. Clinical research in palliative care. J Palliat Med. 2001;115:261-264.